Rocket Pharmaceuticals (RCKT) EBIAT: 2016-2025
Historic EBIAT for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$50.3 million.
- Rocket Pharmaceuticals' EBIAT rose 24.56% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$258.7 million for FY2024, which is 5.35% down from last year.
- Rocket Pharmaceuticals' EBIAT amounted to -$50.3 million in Q3 2025, which was up 26.97% from -$68.9 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' EBIAT ranged from a high of -$34.5 million in Q2 2021 and a low of -$69.6 million during Q2 2024.
- Its 3-year average for EBIAT is -$62.3 million, with a median of -$61.9 million in 2023.
- The largest annual percentage gain for Rocket Pharmaceuticals' EBIAT in the last 5 years was 27.36% (2021), contrasted with its biggest fall of 72.35% (2021).
- Over the past 5 years, Rocket Pharmaceuticals' EBIAT (Quarterly) stood at -$44.2 million in 2021, then plummeted by 50.80% to -$66.7 million in 2022, then increased by 10.59% to -$59.7 million in 2023, then declined by 1.12% to -$60.3 million in 2024, then increased by 24.56% to -$50.3 million in 2025.
- Its EBIAT stands at -$50.3 million for Q3 2025, versus -$68.9 million for Q2 2025 and -$61.3 million for Q1 2025.